Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3668215 A
Publication typeGrant
Publication dateJun 6, 1972
Filing dateNov 12, 1968
Priority dateNov 25, 1967
Also published asDE1670952A1, DE1670952B2, US3755587
Publication numberUS 3668215 A, US 3668215A, US-A-3668215, US3668215 A, US3668215A
InventorsHans Plumpe, Walter Puls
Original AssigneeBayer Ag
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Aryl-sulphonyl-semicarbazides containing heterocyclic acylamino groups
US 3668215 A
Abstract
Oral antidiabetic aryl-sulphonyl-semicarbazides having heterocyclic acylamino groups and pharmaceutical compositions are provided. Typical embodiments are represented by the compounds 4-7/87/84-7/8 beta -[3-methyl-isoxazolyl-(5)-carboxamido]-ethyl}-benzene-sulphonyl}}-1,1- hexamethylene-semicarbazide, 4-[4-7/8 beta -[4,5-tetramethyleneisoxazolyl-(3)-carboxamido]-ethyl}-benzene-sulphon yl]-1,1-hexamethylene-semicarbazide and 4-[3-7/8 beta -[5-methylisoxazolyl-(3)-carboxamido]-ethyl}-benzene-sulphonyl]-1,1-he xamethylene-semicarbazide which are administered in dosages of 1-10 mg/kg to a diabetic host formulated with excipients and tableted or filled into gelatin capsules.
Images(5)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States. Patent Plumpe et al.

[ 1 June 6, 1972 ARYL-SULPHONY L -SEMICARBAZIDES CONTAINING HETEROCYCLIC ACYLAMINO GROUPS Inventorsz Hans Plumpe; Walter Puls, both of Wuppertal-Elberfeld, Germany Assignee: Farvenlabriken Bayer Aktiengesellsciiafl,

Leverkusen, Germany Filed: Nov. 12, 1968 Appl. No.1 775,138

Foreign Application Priority Data Nov. 25, 1969 Germany ..P 16 70 952.7

US. Cl. ..260/307 H, 260/239.8, 260/239.95, 260/247.l, 260/293.58, 260/293.67, 260/293.68, 260/293.7, 260/302 H, 260/307 D, 260/310 R, 424/228, 424/246, 424/248, 424/267, 424/270,

424/272, 424/273 Int. Cl. ..C07d 85/24 Field of Search ..260/307 H, 293.67, 293.58,

References Cited FOREIGN PATENTS OR APPLICATIONS 1,176,310 1/1970 Great Britain Primary Examiner-Alex Mazel Assistant Examiner-R. V. Rush Attorney-Jacobs & Jacobs [57 ABSTRACT Oral antidiabetic aryl-sulphonyl-semicarbazides having heterocyclic acylamino groups and phamiaceutical compositions are provided. Typical embodiments are represented by amethylene-semicarbazide which are administered in dosages of l-lO mg/kg to a diabetic host formulated with excipients and tableted or filled into gelatin capsules.

12 Claims, No Drawings R and R are each hydrogen, halogen atoms, alkyl or aryl, aralkyl or cycloalkyl radicals unsubstituted or substituted by halogen, alkyl, alkoxy or trifluoromethyl,

the grouping I R!!! l N I RIIII is a saturated or unsaturated, monocyclic or polycyclic radical which contains one or more hetero atoms, such as nitrogen, oxygen or sulphur, SO or S and which may be substituted by alkyl, alkoxy, hydroxy or 0x0 groups, and X is oxygen, sulphur, imino or imino substituted by alkyl, aryl or, aralkyl radical which, in turn, is unsubstituted or substituted by halogen, alkyl, alkoxy or trifluoromethyl,

Y is a direct bond, a straight-chain or branched alkyl radical of one to eight carbon atoms, and

n is a whole number from 0 to 4, and the substituents on the benzene ring may be in orthoor meta-, but preferably in para-position to one another. The new compounds, as such or in the form of their alkali metal or alkaline earth metal salts, have a strong blood sugar depressing effect which substantially surpasses that of tolbutamide,

They are therefore intended for use as therapeutic antidiabetic agents to be administered per os for the treatment of diabetes.

These new arylsulphonyl-semicarbazide derivatives are prepared by various methods comprising:

a. reacting a hydrazine of the formula:

NRIIIRIIII in which R and R" have the same meaning as above, as such or in salt form, with an arylsulphonamide derivative which contains heterocyclic acylamino groups and corresponds to the formula:

in which R, R, R, X, Y and n have the same meaning as above, and A is a radical which is released in the course of the reaction with the hydrogen atom attached to the nitrogen of the hydrazine H N-NR"'R with the elimination of a compound HA, or with a corresponding arylsulphonyl-isocyanate:

A being, for example, halogen, azido, alkoxy, aryloxy, alkylmercapto, arylmercapto, unsubstituted or substituted amino, cyclic amino or acylamino; or

b. reacting an arylsulphonarnide of the formula:

in which R, R, R", X, Y and n have the same meaning as above, as such or in the form of their alkali metal salts, with a hydrazine derivative of the formula:

B CO NH NR"R"" or an isocyanate:

OCN NRIIIRIII' in which B is a radical which reacts in the course of the reaction with a hydrogen atom of the sulphonamide group or with the alkali metal atom M of the corresponding sulphonamide alkali metal salt with the elimination of HB or MB; B is, for example, halogen, azido, alkoxy, aryloxy, alkylmercapto, arylmercapto, unsubstituted or substituted amino, cyclic amino or acylamino; or c.'reacting an arylsulphonyl halide of the formula:

in which R, R, R, X, Y and n have the same meaning as above,

and Hal is a halogen atom, preferably chlorine or bromine, with a semicarbazide of the formula:

H NCO-Nl-lNR"'R"" or d. converting an arylsulphonyl compound of the formula:

as above,

into the desired product by oxidative hydrolysis in the case of the thiosemicarbazides (Z SH), by acidic or alkaline hydrolysis in the case of arylsulphonyl-aminoguanidines (Z Nl-l arylsulphonyl-O-alkyl-isosemicarbazides (Z O alkyl), arylsulphonyl-S-alkyl-isosemicarbazides (Z S alkyl) or arylsulphonyl-isosemicarbazide chlorides (Z chlorine); or

e. acylating an amino-(alkyl)-benzene-sulphonyl-semicarbazide of the formula:

in which R, R', R"" and Y have the same meaning as above, with a carboxylic acid or derivative:

Help

in which R, R", X and n have the same meaning as above, and R""' is a group which reacts with the hydrogen atom on the amino group of the reaction component mentioned above with the elimination of R""'l-l; R is, for example, hydroxy, alkoxy, aryloxy or halogen, preferably chlorine; or f. oxidizing a benzene-su]phenyl-semicarbazide (m O) or benzene-sulphinyl-semicarbazide (m l of the formula:

RI! L o R (I) II ik (O1I2)n-CNY som-NH-d-NH-N in which R, R, R", R', R"", X, Y and n have the same meaning as above; or

g. hydrolyzing a parabanic acid derivative of the formula:

l u I /n'" w ll -H-(Ullz)"i[ l I- Y SOz-N N-N\ in which R, R, R", R', R"", X, Y and n have the same meaning as above.

As carboxylic acids from which the heterocyclic acyl radical in the final products of the invention are derived, there may be used, for example: is0xaz0le-(5 )-carboxylic acid, 3-methylisoxazole-( 5 )-carboxylic acid, 5-methylisoxazole-(3)-carboxylic acid, 5-methyl-3- phenylisoxazole-(4)-carboxylic acid, 3-(2', 6-dichlorophenyl)-5-methyl-isoxazole-(4)-carboxylic acid, 3,5-dimethyl-isoxazole-(4)-carboxylic acid, isoxazole-( 3 )-carboxylic acid, isoxazole-(4)-carboxylic acid, 3-methylisoxazole-(4)-carboxylic acid, 5-methylisoxazole-(4)-carboxylic acid, 4,5- dimethylisoxazole-(3)-carboxylic acid, 5-hexylisoxazole-(3)- carboxylic acid, 5-octylisoxazole-(3)-carboxylic acid, S-phenylisoxazole-(3 )-carboxylic acid, 5-tert.-butyl-3-phenyl-isoxazole-(4)-carboxylic acid, 3,5-diphenylisoxazole-(4)-carboxylic acid, 3-ethyl-5-methylisoxazole-4-carboxylic acid, 5- methyl-3-phenylisoxazole-(4)-carboxylic acid, 3-phenylisoxazole-(4)-carboxylic acid, 5-phenylisoxazole-(4)-carboxylic acid, 4-chloro-3-methyl-isoxazole-(4)-carboxylic acid, 3- phenylisoxazole-(S)-carboxylic acid, 4-phenyl-isoxazole-(5)- carboxylic acid, 3,4-tetramethyleneisoxazole-(5)-carboxylic acid, 4,5-tetramethylene-isoxazole-(3)-carboxylic acid, [3- isoxazolyl-(5)-propionic acid, 3,5-dimethyl-isoxazolyl-(4)- acetic acid, isothiazole-(3 )-carboxylic acid, 4-phenylisothiazole-( 3 )-carboxylic acid, 5-phenyl-isothiazole-( 3 )-carboxylic acid, isothiazole-(4)-carboxylic acid, 3-methylisothiazole(4)-carboxylic acid, 3,5-dimethyl-isothiazole-(4)- carboxylic acid, 3,S-dimethyl-isothiazole-(4)-carboxylic acid,

3-methyl-5-benzylisothiazole-(4)-carboxylic acid, 3-methyl-5- ethyl-isothiazole-(4)-carboxylic acid, 3-methyl-5-propylisothiazole-(4)-carboxylic acid, 3-ethyl-5-phenyl-isothiazole- (4)-carboxylic acid, isothiazole-(5)-carboxylic acid, 3-methylisothiazole-(5)-carboxylic acid, 4-methyl-isothiazole-(5)-carboxylic acid, pyrazole-(3)-carboxylic acid, pyrazole-(4)-carboxylic acid, l-methyl-pyrazole-(S)-carboxylic acid, 4- methylpyrazole-(S)-carboxylic acid, 3-methylpyrazole-(4)- carboxylic acid, 3-methylpyrazole-(5)-carboxylic acid, 1- phenylpyrazole-(3)-carboxylic acid, l-phenylpyrazole-(4)- carboxylic acid, 1-phenylpyrazole-(5)-carboxylic acid, 4- phenylpyrazole-(3)-carboxylic acid, 3-phenylpyrazole-(4)- carboxylic acid, 3-phenylphrazole-(5)-carboxylic acid, 3- methyl-1-phenylpyrazole-(4)-carboxylic acid, S-methyll phenylpyra2ole-(4)-carboxylic acid, 5-methyl-l-phenylpyrazole-(3)-carboxylic acid, 3-methyl-l-phenyl-pyrazole-(S )-carboxylic acid, l-methyl-5-phenyl-pyrazole-( 3 )-carboxylic acid, l-methyl-S-phenyl-pyrazole-(S)-carboxylic acid, 4- methyl-3-phenyl-pyrazole-(5)-carboxylic acid, 3-methyl-5- phenyl-pyrazole-(4)-carboxylic acid, 1,4-dimethyl-pyrazole- (3 )-carboxylic acid, 1,4-dimethyl-pyrazole-( 5 )-carboxylic acid, l,5-dimethyl-pyrazole-(3)carboxylic acid, l,3-dimethylpyrazole-(5)-carboxylic acid, l,4-dimethyl-pyrazole-(5)-carboxylic acid, 3,5-dimethyl-pyrazole-(4)-carboxylic acid, 4,5- dimethyl-pyrazole-( 3 )-carboxylic acid.

Suitable compounds for introducing the sulphonamide component into the final products according to the invention are, for example 3-aminobenzene-sulphonamide, 4- aminobenzene-sulphonamide, 4-aminomethylbenzenesulphonamide, 4-(a-aminoethyl)-benzene-sulphonamide, 4- (B-aminoethyl)-benzene-sulphonamide, 4(u-aminopropyl)- benzene-sulphonamide, 4-(B-aminopropyl)-benzenesulphonamide, 4-('y-aminopropyl-sulphonamide), 4-(aamino-a,a-dimethylmethyl)-benzene-sulfonamide, 4-methylaminobenzene-sulphonamide and similar compounds in the form of their base or of salts with acids.

Suitable hydrazines from which the group -NH-NR' "Rin the products according to the invention are derived, are, for example: l-amino-pyrrolidine, l-amino-piperidine, morpholine, 1-amino-hexamethylene-imine, 1-amino-4- methyl-piperideine-(4), N-aminothiamorpholine, N- aminothiamorpholine-S,S-dioxide, N-amino-B-methylthiamorpholine-S,S-dioxide, 3-amino-3-azabicyclo[3,2,0]- heptane, 3-amino-3-azabicyclo[3,2,1l-octane, 6-amino-6- azabicyc1o[3,2,1]-octane, 3-amino-3-azabicyclo[3,2,2]- nonane, 3-amino-3-azabicyclo-[3,3,1l-nonane, 2-amino-2- azabicyclo-[2,2,21-octane, N-amino-nortropane, N-aminogranatanine and their alkyl-substitution products, N-aminocamphidine, N-amino-4,7-endocyclo-propylene-A -hexahydro-isoindole, N-amino-4,7-endocyclobutenylene-A -hexahydro-isoindole, N-amino-4,7-endocyclobutylene-octahydro-isoindole.

Depending on the method of operation, the hydrazines can be used as such or in the form of their derivatives such as carbazidic acid chlorides, carbazidic acid esters or carbazidic acid azides.

The reactions are carried out without or in suitable solvents or diluents; depending on the reactivity of the components, the reaction is itself exothermic or its progress must be brought about or furthered by the use of elevated temperatures. The final products can be converted into therapeutically applicable salts.

Products which contain one or more optically active carbon atoms can be obtained not only in the form of the racemates, but also in their optically active forms, either by using for their preparation, from the start, a corresponding optically active bicyclic amino compound or by subjecting racemic intermediates or final products to a racemate resolution.

EXAMPLE 1 a. 92.8 g (0.3 mole) of 4-{B-[3-methyl-isoxazolyl-(5)-carboxamido1-ethyl}-benzene-sulphonamide (prepared from 3-methyl-isoxazole-(5)-carboxylic acid chloride and N-amino- 4-(B-aminoetyl)-benzene-sulphonamide hydrochloride in pyridine, m.p. 219-220 C.) are heated in 1.5 liters of methyl ethyl ketone with 82.8 g (0.6 mole) of pulverized potassium carbonate under reflux for 40 minutes while stirring. After cooling to room temperature, 47.3 g (0.5 mole) of chloroformic acid methyl ester are added dropwise, the mixture is stirred at room temperature for minutes and under reflux for 4 hours, the product is filtered off with suction while hot and washed with methyl ethyl ketone. The residue is dissolved in water, the solution clarified with activated charcoal, and the filtrate acidified with hydrochloric acid. The resultant precipitate is filtered off with suction, washed with water, and dried. 85.6 g (77 percent of theory) of N-{{4-{l3-[3'-methylisoxazolyl-( 5 )-carboxamido]-ethyl} -benzene-sulfonyl methyl-urethane are obtained in the form of a colorless finely crystalline powder of m.p. 184 C.

7.3 g (0.02 mole) of this compound are dissolved in 150 ml of methanol, 2.5 g (0.022 mole) of N-amino-hexamethyleneimine are added, and the methanol is distilled off, finally under reduced pressure; the residue is finally heated at 110 to 120 C. for 30 minutes, whereupon it solidifies to form a solid mass which is recrystallized from ethanol. 6.2 g (69 percent of theory) of 4- {{4-{B-[3- methyl-isoxazolyl-( 5 )-carboxamido -ethyl} -benzene-sulfonyl}}-l,1-hexamethylene-semicarbazide are obtained in the form of colorless crystals of m.p. 194 C.

EXAMPLE 2 By analogy to Example 1(a), there is obtained from 4-{B- [5-methyl-isoxazolyl-( 3 )-carboxamido]-ethyl} -benzenesulphonamide (prepared from 5-methyl-isoxazole-(3)- carboxylic acid chloride and 4-(B-aminoethyl)-benzenesulphonamide hydrochloride, m.p. 2l3214 C. in pyridine) and chloroformic acid methyl ester, in a yield of 69 percent, the compound N-.{{ -4-{B-[5-methyl-isoxazolyl-( 3 )-carboxamido ]-ethyl} -benzene-sulfonyl methyl-urethane in the form of colorless crystals of m.p.

From the sulphonyl-urethane described above and N- amino-hexamethylene-imine, there is obtained, by analogy to the method described in Example 1(b), in a yield of 70 percent, the compound 4-{{4-{B-[5-methyl-isoxazolyl-( 3 )-carboxamido -ethyl} -benzene-sulphonyl}} l,l-hexamethylene-semicarbazide in the form of colorless crystals of m.p. 189 C.

EXAMPLE 3 By analogy to Example 1(b), there is obtained, from the sulphonyl-urethane prepared according to Example 1(a) and N-amino-isoquinuclidine, the compound 4-{{4-{B-[3-methylisoxazolyl-( 5 )-carboxamido]-ethyl}-benzene-sulphonyl}} 1,1-[ 1', 4'-ethano)-pentamethylene-semicarbazide] in the form of colorless crystals of m.p. 197 C.

EXAMPLE 4 By analogy to Example 1(b), there is obtained, from the sulphonyl-urethane prepared according to Example 2(a) and N-amino-isoquinuclidine, the compound 4- {{4-{B-[5-methylisoxazolyl-( 3 )-carboxamido]-ethyl} -benzene-sulphonyl}} l ,1-[1 ',4'-ethano]-pentamethylene-semicarbazide in the form of colorless crystals of m.p. 190 C.

Furthermore, with Naminopiperidine, the compound 4-{{4 -{B- 5-methylisoxazolyl-( 3 )-carboxamido]-ethyl}-benzenesulphonyl}}-1,1-pentamethylene-semicarbazide of m.p. 185 C.; with N-aminomorpholine, the compound 4- {{4- {,13-[5- methylisoxazolyl-( 3 )-carbonamido ]-ethyl}-benzene-sulphonyl}}-1,l-(oxydiethylene)semicarbazide of m.p. 174 C.; with 3-methyl-4-aminothiomorpholinel -dioxide, the compound 4-{ {4-{13-[5-methylisoxazolyl-( 3 )-carboxamido]-ethyl }-benzenesulphonyl }}-l 1( 2-methyl-sulphonyl-diethylene)-semicarbazide of m.p. 180 C.

EXAMPLE 5 4[ 3-methylisoxazolyl-( 5 )-carboxamido]-benzene-sulphonamide, m.p. 249 C. (prepared from 3-methylisoxazole-(5 )-carboxylic acid chloride and 4-aminobenzenesulphonamidehydrochloride in pyridine), by analogy to Example 1(a) with chloroformic acid methyl ester is transformed into the corresponding sulphonyl-urethane of m.p. 244 C. Similarly to Example 1(b) there is obtained therefrom with N-aminohexamethyleneimine, the compound 4-{4-[3-methylisoxazolyl- (5)-carboxamido]-benzenesulphonyl}-1,l-hexamethylenesemicarbazide as a colorless fine crystalline powder of m.p. 227 C., and with N-amino-morpholine, the compound 4- {4- [3-methylisoxazolyl-( 5 )-carboxamido]-benzene-sulphonyl}- 1,1-(oxydiethylene)-semicarbazide of m.p. 243 C.

EXAMPLE 6 4-[ 5-methylisoxazolyl-( 3 )-carboxamidomethyl]- benzenesulphonamide of m.p. 210 C. (prepared from 5- methyl-isoxazole-(3)-carboxylic acid chloride and 4- aminomethyl-benzenesulphonamide hydrochloride in pyridine) is by analogy to Example 1(a) with chloroformic acid methyl ester transformed into the corresponding sulphonyl-urethane, i.e., N- {{4-[5-methylisoxazolyl-(3)-carboxamido]-methyl-benzene-sulphonyl }}-methyl-urethane, of m.p. 172 C. Similarly to Example 1(b) there is obtained therefrom with N-aminohexamethylene-imine the compound 4- {4-[5-methylisoxazolyl-( 3 )-carboxamidomethyl]- benzenesulphonyl} l ,1-hexamethylene-semicarbazide of m.p. 180 C., as a colorless fine crystalline powder, and with N- aminomorpholine, the compound 4-{4-[5 -methylisoxazolyl- (3 )-carboxamidomethyl]-benzenesulphonyl}-1 1 -(oxydiethylene)-semicarbazide of m.p. 225 C.

EXAMPLE 7 4-{a-[S-methylisoxazolyl-(3)-carboxamido]-ethyl}- benzenesulphonamide of m.p. 169 to 171 C., (prepared from 5-methylisoxazole-(3)-carboxlyic acid chloride and 4- (a-aminoethyl)-benzene-sulphonamide in pyridine) by analogy to Example 1(a) with chloroformic acid methyl ester is transformed into the corresponding sulphonylmethylurethane of m.p. F. 74 C. Therefrom there is obtained similarly to Example 1(b) with N-aminohexamethyleneimine the compound 4- 4-{a-[ 5-methyl-isoxazolyl-( 3 )-carboxamido] -ethyl benzene-sulphonyl }}-1,l-hexamethylene-semicarbazide m.p. 181 C., as a colorless fine crystalline powder.

EXAMPLE 8 Similarly to Example 2(a) there is obtained from 4-{a-[5- methylisoxazolyl-( 3 )-carboxamido]-propyl }-benzenesulphonarnide (prepared from 5-methylisoxazole-3-carboxylic acid chloride and 4-(a-aminopropyl)-benzenesulphonamidehydrochloride in pyridine of m.p. C.) and chloroformic acid methyl ester, the compound N-[4-{a-[5-methylisoxazolyl-( 3 )-carboxamido]-propyl} -benzenesulphony1]- methylurethane of m.p. 146148 C., and therefrom similarly to Example 2(b) with N-aminohexamethylene-imine, the compound 4-[4-{a-[5-methylisoxazolyl-( 3 )carboxamido]- propyI}-benzenesulphonyl ]-1 l-hexamethylene-semicarbazide ofm.p. 161 C.

EXAMPLE 9 Similarly to Example 2(a) there is obtained from 4-{B-[4,5-

tetramethylene-isoxazolyl-(3)-carboxamido]-ethyl}- benzenesulphonamide (prepared from 4,5-tetramethyleneisoxazole-3-carboxylic acid chloride and 4-(B-aminoethyl)- benzenesulphonarnide-hydrochloride, in pyridine of m.p. 175 C.) and chloroformic acid methyl ester the compound N-[4-{ B-[4,5-tetramethylene-isoxazolyl-( 3 )-carboxamido ]-ethyl}- benzenesulphonyl]-urethane of m.p. 172 C. and therefrom by analogy to EXAMPLE 2(b) with N-aminohexamethyleneimine, the compound 4-[4-{B-[4,5- tetramethylene-isoxazolyl-( 3 )-carboxamido ]-ethyl benzenesulphonyl1- l 1-hexamethylene-semicarbazide of m .p. C.

EXAMPLE l0 Similarly to Example 2(a) there is obtained from 4-{B-[1,5- dimethyl-pyrazlyl-( 3 )-carboxamido]-ethyl}-benzenesulphonamide (produced from 1,5-dimethylpyrazole-3-carboxylic acid chloride and 4-(B-aminoethyl)-benzenesulphonamide-hydrochloride in pyridine of m.p. 225 C.) and chloroformic acid methyl ester, the compound N-[4-{B-[ 1,5- dimethylpyrazolyl-( 3 )-carboxamido]-ethyl}-benzenesulphonyll-methyl-urethane of m.p. 211 C., and therefrom similarly to Example 2(b) with hexamethyleneimine, the compound 4- [4-{B-[ l ,5-dimethylpyrazolyl-( 3 )-carboxamido-ethyl}- benzenesulphonyl]-1, l-hexamethylene-semicarbazide of m.p. 1 86l 88 C.

EXAMPLE 1] Similarly to Example 2(a) there is obtained from 4-{13-[3- methylisothiazolyl-(S)-carboxamido]-ethyl}- benzenesulphonamide (prepared from 3-methylisothiazole- ()-carboxylic acid chloride and 4-(B-aminoethyl)- benzenesulphonamidehydrochloride in pyridine of m.p. 190 C.) and chloroformic acid methyl ester, the compound N-[4-{ ,B-[ 3-methylisothiazolyl-( 5 )-carboxamido]-ethyl}-' benzenesulphonyl]-methylurethane of m.p. 161 C., and

therefrom similarly to Example 2 (b) with N-aminohexamethyleneimine, the compound 4-[4-{B-[3-methylisothiazolyl-( 5 )-carboxamido]-ethyl}-benzenesulphonyl]- l l hexamethylene-semicarbazide of m.p. 171 C.

EXAMPLE 12 Similarly to Example 2(a) there is obtained from 3-{B-[5- methylisoxazolyl-(3)-carboxamido]-ethyl}-benzenesulphonyl (prepared from 5-methyl-isoxazole-3-carboxylic acid chloride and 3(B-amidoethyl)-benzenesulphonamide-hydrochloride in pyridine of m.p. 1 15 C.) and chloroformic acid methyl ester, the compound N-[3{B-[5-methylisoxazolyl-(3)-carboxamido]-ethy1}-benzenesulphonyl]-methylurethane of m.p. 143 C., and therefrom with N-amino-hexamethylene-imine like 2(b), the compound 4-[3-{,8-[5-methylisoxazolyl-(3)-carboxamidol-ethyl}-benzene-sulphonyl]-1,1-hexamethylenesemicarbazide of m.p. 183 C.

The blood sugar lowering action of 4-[4 -{B-[5-methylisoxazolyl-( 3 )-carbozamido]-ethyl} -benzenesulphonyl]-1 l-hexamethylene-semicarbazide, in comparison to 4-(4-tolylsulphonyl l l-hexamethylene-semicarbazide (Tolazamide) as to ingestion at the start of the tests of fed rats:

Blood Sugar in of the Starting Value 4-[ 4- {B-[ S-methyl- Tolazamide isoxazolyl-( 3 -carboxamidol-ethyli-benzenesulphonyl]- l ,l-hexamethylene-semicarbazide Dosage mg/kg Hours after Administration 1.5 86 57 97 57 3.0 92 76 lOO 86 TABLETS The finely pulverized active substance is thoroughly mixed with the requisite additives and compressed into tablets so that each tablet contains the following substances:

1 mg 4-[4-{,B-[5-methylisoxazolyl-( 3 )-carboxamido]-ethyl} -benzene-sulphonyl]-l ,1 -hexamethylene-semi-carbazide 8 10 mg Colloidal silica 20 mg Cornstarch 1 mg Magnesium stearate 68 mg Lactose Hard Gelatin Capsules The finely pulverized active substance is mixed with the requisite additives and filled into capsules so that each capsule contains the following substances:

1 mg 4-[4-{B-[5-methylisoxazolyl-( 3)-carb'oxamido]-ethyl} -benzene-sulphonyl]- l ,1 -hexamethylene-semi-carbazide 79 mg Lactose 10 mg Cornstarch What is claimed is: l. A sulphonyl-semicarbazide having heterocyclic acylamino groups and corresponding to the formula:

in which R is hydrogen or methyl,

R and R are each hydrogen, halogen, alkyl of one to eight carbon atoms, or together tetrarnethylene in the 4,5 positron,

R' and R together are alkylene of four to six carbon atoms unsubstituted or substituted by methyl, and

X is oxygen,

Y is a direct bond or straightor branched-chain alkyl of one to three carbon atoms; and

n is a whole number from O to 4, the substituents on the benzene ring being ortho-, metaor parato one another,

or a pharmaceutically acceptable non-toxic alkali metal or alkaline earth metal salt thereof.

2. An alkali metal or alkaline earth metal salt of a compound ofclaim l.

3. A compound of claim 1 in which the substituents on the benzene ring are in the para-position to one another.

4. The compound 4- {{4-{/3-[3-methyl-isoxazolyl-(5 )-carboxamido]-ethyl} -benzene-sulphonyl}}- l l -hexamethylenesemicarbazide.

5. The compound 4-[4-{,8[4,5-tetramethylene-isoxazolyl- (3 )-carboxamido]-ethyl} -benzenesulphonyl]- 1 l -hexamethylene-semicarbazide.

6. The compound 4-[3-{B-[5-methylisoxazolyl-(3)-carb0xamido]-ethyl} -benzenesulphonyl l l -hexamethylenesemicarbazide.

7. The compound 4-{{4-{B-[5-methyl-isoxazolyl-(3)-carboxamido]-ethyl}-benzenesulphonyl }}l l-hexamethylenesemicarbazide.

8. The compound according to claim 1 which is: 4- {{4- {B-[ 5-methyl-isoxazolyl-( 3 )-carboxamido]-ethyl}- benzenesulphonyl l l-pentamethylene-semicarbazide.

9. The compound according to claim 1 which is: 4-{4-[3- methyl-isoxazolyl-( 5 )-carboxamido]-benzenesulphonyl} -1 l hexamethylene-semicarbazide.

10. The compound according to claim 1 which is: 4-{4-[5- methyl-isoxazolyl-( 3 )-carboxamido-methyl]-benzenesulphonyl}- l l-hexamethylene-semicarbazide.

11. The compound according to claim 1 which is: 4- {{4- {a- 5-methyl-isoxazolyl-( 3 )-carboxamido]-ethyl} benzenesulphonyl l l -hexamethylene-semicarbazide.

12. The compound according to claim 1 which is: 4-[4-{a-[ 4-methyl-isoxazolyl-( 3 )-carboxamido]-propyl}- benzenesulphonyl]-1,l-hexamethylenesemicarbazide.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
GB1176310A * Title not available
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US4153710 *Dec 20, 1977May 8, 1979Starogardzkie Zaklady Farmaceutyczne PolfaN-(4-[2-(pyrazole-1-carbonamide)-ethyl]-benzenesulphonyl)-urea
US4696815 *May 31, 1984Sep 29, 1987Gottfried SchepkyAnti-diabetic pharmaceutical forms and the preparation thereof
US4708868 *May 31, 1984Nov 24, 1987Dr. Karl Thomae GmbhOral anti-diabetic pharmaceutical forms and the preparation thereof
US5780393 *Aug 23, 1996Jul 14, 1998American Cyanamid CompanyHerbicidal isoxazole and isothiazole-5-carboxamides
US7976871May 19, 2005Jul 12, 2011Torrent Pharmaceuticals LimitedModified release composition of highly soluble drugs
US8012931Mar 19, 2008Sep 6, 2011Ambrx, Inc.Modified FGF-21 polypeptides and their uses
US8216609Jul 10, 2012Torrent Pharmaceuticals LimitedModified release composition of highly soluble drugs
US8268352May 19, 2005Sep 18, 2012Torrent Pharmaceuticals LimitedModified release composition for highly soluble drugs
US8383365Feb 26, 2013Ambrx, Inc.Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives
US9079971Jan 2, 2013Jul 14, 2015Ambrx, Inc.Modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US20040096501 *Jul 29, 2003May 20, 2004Navin VayaNovel drug delivery system
US20060018933 *May 19, 2005Jan 26, 2006Navin VayaNovel drug delivery system
US20060018934 *May 19, 2005Jan 26, 2006Navin VayaNovel drug delivery system
US20080255045 *Mar 19, 2008Oct 16, 2008Ambrx, Inc.Modified FGF-21 Polypeptides and Their Uses
US20110172401 *Jul 14, 2011Ambrx, Inc.Modified FGF-21 Polypeptides and Their Uses
Classifications
U.S. Classification548/209, 544/139, 544/140, 548/374.1, 548/247, 548/248, 544/133, 548/241, 546/211, 548/214, 514/866, 546/209, 548/375.1, 548/312.4, 544/137
International ClassificationC07D453/06, C07D275/02, C07D261/20, C07D261/18, C07D231/14, C07D275/03
Cooperative ClassificationC07D261/18, C07D231/14, C07D261/20, C07D275/03, C07D453/06, Y10S514/866, C07D275/02
European ClassificationC07D453/06, C07D261/18, C07D261/20, C07D231/14, C07D275/03, C07D275/02